TNF alpha Antibody | Affinity Biosciences

WB
IHC
IF/ICC
Cites

1/106

Western blot analysis of extracts from rat brain, using TNFA Antibody.

Western blot analysis of extracts from various samples, using TNFA Antibody.

AF7014 at 1/100 staining Human colorectal cancer by IHC-P.

AF7014 at 1/100 staining Human mammary cancer by IHC-P.

AF7014 at 1/100 staining Human normal tissues adjacent to lung cancer by IHC-P.

AF7014 at 1/100 staining Rat colon tissue by IHC-P.

AF7014 staining Hela cells by IF/ICC.

$Fig. 7 a Western blot analysis demonstrates levels of TNF-a and IL-1b in the hippocampus of rats at 12, 24, and 48 h following TBI or sham operation (n = 5/group). b Densitometry of the TNF-a and IL-1b band correlated to the b-actin band. The bars represent the mean ± SE (n = 5/group). The results demonstrated that a significant increase of TNF-a and IL-1b expression in the TBI group (*p\0.01 vs. sham group), and treatment with TAK-242 significantly downregulated the level of TNF-a and IL-1b protein expression at 12, 24, and 48 h following TBI (# p\0.05 vs. TBI group). TNF-a, tumor necrosis factor-a; IL-1b, interleukin-1b$

Fig.

The expression levels of IL-6 and TNF-α in the cerebral tissues of vehicle group were increased significantly in comparison with that of the control group.

FIGURE 3: Pro-inflammatory factors, anti-oxidant enzyme and cell signaling pathways in resveratrol (Res)- or vehicle-treated cystic kidneys.

Figure 7.

Figure 5.

Figure 4:| Tight junction protein expression is positively correlated with that of inflammatory cytokines after neonatal hyperoxia.

Figure 6.

Fig.

FIGURE 7 Zinc can reduce the inflammation of damaged parts by inhibiting ferroptosis.

Fig.

FIGURE 6| (a) Immunohistochemical evaluation of vascular endothelial growth factor (VEGF),TNF-a, IL-6, and IL-1b in Zone 2 of the two groups, observed under original magnification 400.

Fig.

Figure 5: |Western blot image of pituitary gland protein expressions in rats.

Figure 7.

Fig.

Figure 2 Treatment with liraglutide decreased the inflammatory response at both the mRNA and protein levels.

Fig.

Figure 12–Effects of fungal proteins extracted from Hericium erinaceus on tumor tissues in xenografted cancer mice.

Fig.

Figure 2 Treatment with liraglutide decreased the inflammatory response at both the mRNA and protein levels.

Fig.

FIGURE 4|FKN regulated polarization in LPS-induced J774A.

Fig.

Figure 3 Ac-SDKP reduces lung inflammation and activation of TLR4 signaling in rats exposed to silica.

Fig.

Figure 6 PARP1 inhibitor attenuates renal ischemia-reperfusion injury.

FIGURE 3 ATL attenuates intestinal inflammation of DSS-induced colitis in mice (A) Immunohistochemistry of inflammatory cytokines (TNF-α, IL-6, and IL-1β) (B) Immunofluorescent staining of macrophages (F4/80, iNOS) (C) Representative western blots of p-p38, p38, p-JNK, JNK, p-ERK, and ERK in colon tissue (D–F) Relative density of each signaling band was calculated.

Figure 5.

Fig.

Figure 5 Bovine miR-125b regulates the expression of NF-κB, TNF-α and IL-6 in LPS-induced MAC-T cells.

Figure 4:| TT inhibited the inflammatory activation of microglia and astrocytes.

Fig.

FIG 2 Sa reduces the production of proinflammatory cytokines in the kidney of LPS-induced mice.

FIGURE 5 | WMW reduces colonic inflammatory responses in DSS-induced colitis.

Fig.

Figure 3:| Inflammatory factor (IL-1β, IL-6, and TNF-α) protein expression.

Figure 12|The protein expression levels of TNF-α, IL-6, MMP9, MAPK8, PI3K, NF-κB, and IκBα in blood (n = 3).

Fig.

$Figure 1 Cardiomyocyte-specific ablation of TAB2 leads to dilated cardiomyopathy in mice. (A) Western blotting for the indicated proteins in ventricular extracts from Tab2fl/fl, MerCreMer (MCM), and Tab2fl/fl-MCM mice 2 weeks after treatment with tamoxifen as described in Methods. TAB2 protein level was normalized for the internal control GAPDH and expressed as fold change. *P < 0.05 versus Tab2fl/fl or MCM. n = 4. (B and C) Masson’s trichrome–stained, paraffin-embedded cardiac sections from mice as described in A. Scale bars: 1 mm in B and 50 μm in C. (D) Myocardial fibrosis quantified with MetaMorph software. *P < 0.05 versus Tab2fl/fl or MCM. n = 5–7. (E) Western blot (left) and quantification (right) of the indicated proteins normalized to GAPDH in cardiac extracts from mice indicated in A. (F) Heart weight to body weight ratio (HW/BW) of mice of the indicated genotypes. *P < 0.05 versus Tab2fl/fl or MCM. (G) Lung weight to body weight ratio (LW/BW) of mice of the indicated genotypes. *P < 0.05 versus Tab2fl/fl or MCM. (H) Representative echocardiographic M-mode images from mice indicated in A. The vertical white arrowed lines indicate left ventricular dimension in end-diastole (LVED). (I–K) Echocardiographic assessment of fractional shortening (FS) and left ventricular dimension in end-diastole (LVED) and end-systole (LVES) in mice of the indicated genotypes. *P < 0.05 versus Tab2fl/fl or MCM. n = 5–7. Statistical analysis was performed using 1-way ANOVA with Tukey’s post hoc test.$

Figure 1 Cardiomyocyte-specific ablation of TAB2 leads to dilated cardiomyopathy in mice.

Figure 6| Immunohischemistry representative photomicrographs and scores for IL-6, TNF-α and IL-1β in the blank control group and 0.

Figure 4 Calcitriol inhibited MI-induced cardiac myocyte apoptosis and death, as well as inflammation by modulating VDR signaling.

Fig.

Figure 2 ESPs supplementation suppressed microglial activation and inflammation in the hippocampus and prefrontal cortex of HF diet-induced obese mice.

FIGURE 2 MaR1 inhibited inflammation and renal cell apoptosis in lipopolysaccharide (LPS)-induced S-AKI mice.

Figure 2 AOPPs up-regulate NOX4 expression, induce senescence in AF cells, and increase the secretion of senescence-associated inflammatory proteins.

Figure 7 Blocking NOX4 expression in vivo by AAV delays IVDD.

Figure 6 In vitro experimental further verifies the effects of palovarotene and Smad and NF-κB signaling pathways in HO.

Fig.

Figure 3.

Figure 2 Amelioration of lipid accumulation in PA-induced HepG2 cells by FV.

Figure 3.

Fig.

Figure 1 Diabetes Aggravates STING-Mediated Inflammation in Hearts.

Figure 7.

Figure 5.

Figure 7 (A) Immunohistochemistry images of IL-1β, IL-6 and TNF-α.

Figure 2 CVB-D inhibits cellular iron-overload induced by LPS.

Figure 5 Comparison results of TNF-α and IL-6 expression in the enthesis fibrocartilage (FC) area.

Fig.

FIGURE 8 (A) Magnification after immunohistochemical staining of hypoxia‐inducible factor‐1α (HIF‐1α) and vascular endothelial growth factor (VEGF) on day 7.

Fig.

Figure 5 The IL-6/STAT3 signaling pathways were activated in CAG gastric tissue.

Fig.

Figure 10.

Figure 3 Expression of PTGS2, FOS, JUN, EDN1 and TNF-α in NPCs.

Fig.

Product:	TNF alpha Antibody
Catalog:	AF7014
Description:	Rabbit polyclonal antibody to TNF alpha
Application:	WB IHC IF/ICC
Reactivity:	Human, Mouse, Rat
Prediction:	Pig, Bovine, Sheep, Dog
Mol.Wt.:	17kD(soluble),25-35kD(membrane); 26kD(Calculated).
Uniprot:	P01375
RRID:	AB_2835319

View similar products>>

Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific.

Size	Price	Inventory
50ul	$250	In stock
100ul	$350	In stock
200ul	$450	In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Related Downloads

MSDS

Data Sheet

COA

Protocols

WB Handbook

IHC Protocol

IF/ICC Protocol

Product Info

Source:

Rabbit

Application:

WB 1:500, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:

Human,Mouse,Rat

Prediction:

Pig(100%), Bovine(90%), Sheep(90%), Dog(90%)

Clonality:

Polyclonal

Specificity:

TNF alpha Antibody detects endogenous levels of total TNF alpha.

RRID:

AB_2835319
Cite Format: Affinity Biosciences Cat# AF7014, RRID:AB_2835319.

Conjugate:

Unconjugated.

Purification:

The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).

Storage:

PBS, pH 7.4,50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.

Alias:

Fold/Unfold

APC1; APC1 protein; Cachectin; DIF; Differentiation inducing factor; Macrophage cytotoxic factor; Tnf; TNF superfamily, member 2; TNF, macrophage derived; TNF, monocyte derived; TNF-a; TNF-alpha; TNFA; TNFA_HUMAN; TNFSF2; Tumor necrosis factor alpha; Tumor necrosis factor; Tumor necrosis factor ligand superfamily member 2; Tumor Necrosis Factor, Membrane Form; Tumor necrosis factor, soluble form;

Immunogens

Immunogen:

Uniprot:

P01375(TNFA_HUMAN) >>Visit HPA database.

Gene(ID):

TNF(7124)

Description:

This gene encodes a multifunctional proinflammatory cytokine that belongs to the tumor necrosis factor (TNF) superfamily. This cytokine is mainly secreted by macrophages. It can bind to, and thus functions through its receptors TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. This cytokine is involved in the regulation of a wide spectrum of biological processes including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation.

Sequence:

P01375 TNFA_HUMAN:
Protein BLAST With
NCBI/
ExPASy/
Uniprot

MSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLIVAGATTLFCLLHFGVIGPQREEFPRDLSLISPLAQAVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELRDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species

Results

Score

Pig

100

Bovine

Sheep

Dog

Horse

Xenopus

Zebrafish

Chicken

Rabbit

Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P01375 As Substrate

P01375

Site	PTM Type	Enzyme	Source
S2	Phosphorylation	Q8N165 (PDIK1L)	Uniprot
K19	Myristoylation		Uniprot
K20	Myristoylation		Uniprot
S80	O-Glycosylation		Uniprot
S162	Phosphorylation		Uniprot
S171	Phosphorylation		Uniprot

Research Backgrounds

P01375_TNFA_HUMAN

Function:

Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Upregulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective. Key mediator of cell death in the anticancer action of BCG-stimulated neutrophils in combination with DIABLO/SMAC mimetic in the RT4v6 bladder cancer cell line. Induces insulin resistance in adipocytes via inhibition of insulin-induced IRS1 tyrosine phosphorylation and insulin-induced glucose uptake. Induces GKAP42 protein degradation in adipocytes which is partially responsible for TNF-induced insulin resistance (By similarity).

The TNF intracellular domain (ICD) form induces IL12 production in dendritic cells.

PTMs:

The soluble form derives from the membrane form by proteolytic processing. The membrane-bound form is further proteolytically processed by SPPL2A or SPPL2B through regulated intramembrane proteolysis producing TNF intracellular domains (ICD1 and ICD2) released in the cytosol and TNF C-domain 1 and C-domain 2 secreted into the extracellular space.

The membrane form, but not the soluble form, is phosphorylated on serine residues. Dephosphorylation of the membrane form occurs by binding to soluble TNFRSF1A/TNFR1.

O-glycosylated; glycans contain galactose, N-acetylgalactosamine and N-acetylneuraminic acid.

Subcellular Location:

Cell membrane>Single-pass type II membrane protein.

Membrane>Single-pass type II membrane protein.

Secreted.

Secreted.

Secreted.

Subunit Structure:

Homotrimer. Interacts with SPPL2B.

Family&Domains:

Belongs to the tumor necrosis factor family.

Research Fields

· Cellular Processes > Cell growth and death > Apoptosis. (View pathway)

· Cellular Processes > Cell growth and death > Necroptosis. (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway. (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction. (View pathway)

· Environmental Information Processing > Signal transduction > NF-kappa B signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Sphingolipid signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > mTOR signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > TGF-beta signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > TNF signaling pathway. (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > Antifolate resistance.

· Human Diseases > Endocrine and metabolic diseases > Type II diabetes mellitus.

· Human Diseases > Endocrine and metabolic diseases > Insulin resistance.

· Human Diseases > Endocrine and metabolic diseases > Non-alcoholic fatty liver disease (NAFLD).

· Human Diseases > Endocrine and metabolic diseases > Type I diabetes mellitus.

· Human Diseases > Neurodegenerative diseases > Alzheimer's disease.

· Human Diseases > Neurodegenerative diseases > Amyotrophic lateral sclerosis (ALS).

· Human Diseases > Infectious diseases: Bacterial > Pertussis.

· Human Diseases > Infectious diseases: Bacterial > Legionellosis.

· Human Diseases > Infectious diseases: Parasitic > Leishmaniasis.

· Human Diseases > Infectious diseases: Parasitic > Chagas disease (American trypanosomiasis).

· Human Diseases > Infectious diseases: Parasitic > African trypanosomiasis.

· Human Diseases > Infectious diseases: Parasitic > Malaria.

· Human Diseases > Infectious diseases: Parasitic > Toxoplasmosis.

· Human Diseases > Infectious diseases: Parasitic > Amoebiasis.

· Human Diseases > Infectious diseases: Bacterial > Tuberculosis.

· Human Diseases > Infectious diseases: Viral > Hepatitis C.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Infectious diseases: Viral > HTLV-I infection.

· Human Diseases > Infectious diseases: Viral > Herpes simplex infection.

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

· Human Diseases > Immune diseases > Asthma.

· Human Diseases > Immune diseases > Inflammatory bowel disease (IBD).

· Human Diseases > Immune diseases > Systemic lupus erythematosus.

· Human Diseases > Immune diseases > Rheumatoid arthritis.

· Human Diseases > Immune diseases > Allograft rejection.

· Human Diseases > Immune diseases > Graft-versus-host disease.

· Human Diseases > Cardiovascular diseases > Hypertrophic cardiomyopathy (HCM).

· Human Diseases > Cardiovascular diseases > Dilated cardiomyopathy (DCM).

· Organismal Systems > Development > Osteoclast differentiation. (View pathway)

· Organismal Systems > Immune system > Antigen processing and presentation. (View pathway)

· Organismal Systems > Immune system > Toll-like receptor signaling pathway. (View pathway)

· Organismal Systems > Immune system > NOD-like receptor signaling pathway. (View pathway)

· Organismal Systems > Immune system > RIG-I-like receptor signaling pathway. (View pathway)

· Organismal Systems > Immune system > Hematopoietic cell lineage. (View pathway)

· Organismal Systems > Immune system > Natural killer cell mediated cytotoxicity. (View pathway)

· Organismal Systems > Immune system > IL-17 signaling pathway. (View pathway)

· Organismal Systems > Immune system > T cell receptor signaling pathway. (View pathway)

· Organismal Systems > Immune system > Fc epsilon RI signaling pathway. (View pathway)

· Organismal Systems > Endocrine system > Adipocytokine signaling pathway.

References

1). Bioactive antiinflammatory antibacterial hemostatic citrate-based dressing with macrophage polarization regulation for accelerating wound healing and hair follicle neogenesis. Bioactive Materials (PubMed: 33005834) [IF=18.9]

Application: IF/ICC Species: Mice Sample: wound tissues

Fig. 8 Immunofluorescence of inflammatory factor TNFα on wound tissue sections after treating by dressing at day 3. (A)The green channel showed TNFα expression while the sections were counterstained with DAPI; (B) The number of TNFα positive cells per mm2 were counted in each group; (C) Relative fluorescence intensity of TNFα expression. (**p < 0.01 and ***p < 0.001 relative to all other groups).

2). Functionally integrating nanoparticles alleviate deep vein thrombosis in pregnancy and rescue intrauterine growth restriction. Nature Communications (PubMed: 36418325) [IF=16.6]

3). TAB2 deficiency induces dilated cardiomyopathy by promoting RIPK1-dependent apoptosis and necroptosis. The Journal of Clinical Investigation (PubMed: 34990405) [IF=15.9]

Application: WB Species: Mice Sample:

Figure 1 Cardiomyocyte-specific ablation of TAB2 leads to dilated cardiomyopathy in mice. (A) Western blotting for the indicated proteins in ventricular extracts from Tab2fl/fl, MerCreMer (MCM), and Tab2fl/fl-MCM mice 2 weeks after treatment with tamoxifen as described in Methods. TAB2 protein level was normalized for the internal control GAPDH and expressed as fold change. *P < 0.05 versus Tab2fl/fl or MCM. n = 4. (B and C) Masson’s trichrome–stained, paraffin-embedded cardiac sections from mice as described in A. Scale bars: 1 mm in B and 50 μm in C. (D) Myocardial fibrosis quantified with MetaMorph software. *P < 0.05 versus Tab2fl/fl or MCM. n = 5–7. (E) Western blot (left) and quantification (right) of the indicated proteins normalized to GAPDH in cardiac extracts from mice indicated in A. (F) Heart weight to body weight ratio (HW/BW) of mice of the indicated genotypes. *P < 0.05 versus Tab2fl/fl or MCM. (G) Lung weight to body weight ratio (LW/BW) of mice of the indicated genotypes. *P < 0.05 versus Tab2fl/fl or MCM. (H) Representative echocardiographic M-mode images from mice indicated in A. The vertical white arrowed lines indicate left ventricular dimension in end-diastole (LVED). (I–K) Echocardiographic assessment of fractional shortening (FS) and left ventricular dimension in end-diastole (LVED) and end-systole (LVES) in mice of the indicated genotypes. *P < 0.05 versus Tab2fl/fl or MCM. n = 5–7. Statistical analysis was performed using 1-way ANOVA with Tukey’s post hoc test.

4). Fecal microbiota transplantation protects rotenone-induced Parkinson’s disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis. Microbiome (PubMed: 34784980) [IF=15.5]

Application: WB Species: Mice Sample: colon tissue

Fig. 5 FMT treatment suppresses the generation of pro-inflammatory molecules both in the SN and the colon of rotenone-challenged mice. A Representative western blot brands of TNF-α, IL-1β, IL-6, iNOS, and COX2 in the midbrain containing the SN. B–F The density analysis results of TNF-α, IL-1β, IL-6, iNOS, and COX2 in the midbrain containing the SN. G TNF-α levels in the midbrain containing the SN. H Representative western blot brands of TNF-α, IL-1β, IL-6, iNOS, and COX2 in the colon. I–M The density analysis results of TNF-α, IL-1β, IL-6, iNOS, and COX2 in the colon. N TNF-α levels in the colon. For B–F and I–M, n = 4 for each group. For G and N, n = 8 for each group. Data are presented as mean ± SD. #P < 0.05, ##P < 0.01, ###P < 0.001 versus the control group; *P < 0.05, **P < 0.01, ***P < 0.001 versus the rotenone group

5). Life-threatening viral disease in a novel form of autosomal recessive IFNAR2 deficiency in the Arctic. JOURNAL OF EXPERIMENTAL MEDICINE (PubMed: 35442417) [IF=15.3]

6). Polydopamine nanoparticles as dual-task platform for osteoarthritis therapy: A scavenger for reactive oxygen species and regulator for cellular powerhouses. Chemical Engineering Journal [IF=15.1]

7). Upregulation of BCL-2 by acridone derivative through gene promoter i-motif for alleviating liver damage of NAFLD/NASH. NUCLEIC ACIDS RESEARCH (PubMed: 32710621) [IF=14.9]

Application: WB Species: mouse Sample: liver

Figure 7. Effect of A22 on ameliorating apoptosis, ER stress, inflammation, metabolic syndrome, and fibrogenesis in HF diet-fed mice. (A) Effect of A22 on BCL-2 gene transcription. (B) Effect of A22 on BAX gene transcription. (C) Effect of A22 on expressions of apoptosis-related proteins in liver. The extracted proteins from the liver were immunoblotted with specific antibodies, and quantified based on the loading control of ACTIN. (D) Effect of A22 on ER stress. The UPR proteins (IRE-1, PERK, elF-2 and CHOP) were analyzed by using western Blot. (E) Effect of A22 on expressions of inflammatory factors. (F) Effect of A22 on expressions of fibrogenic proteins.

8). An injectable antibacterial chitosan-based cryogel with high absorbency and rapid shape recovery for noncompressible hemorrhage and wound healing. BIOMATERIALS (PubMed: 35552114) [IF=14.0]

9). Electrical stimulation of piezoelectric BaTiO3 coated Ti6Al4V scaffolds promotes anti-inflammatory polarization of macrophages and bone repair via MAPK/JNK inhibition and OXPHOS activation. BIOMATERIALS (PubMed: 36586147) [IF=14.0]

10). Folic acid targets splenic extramedullary hemopoiesis to attenuate carbon black-induced coagulation-thrombosis potential. JOURNAL OF HAZARDOUS MATERIALS (PubMed: 34634699) [IF=13.6]

Restrictive clause

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.

TNF alpha Antibody - #AF7014

Related products

Related Downloads

MSDS

Data Sheet

COA

Protocols

WB Handbook

IHC Protocol

IF/ICC Protocol

Product Info

Immunogens

Predictions

PTMs - P01375 As Substrate

Research Backgrounds

Research Fields

References

Restrictive clause